Investor Presentation

AI summary - Q2 FY27 revenue 4,423 Cr +1% y-y; EBITDA 865 Cr (20% margin, down 200 bps y-y); net profit 41 Cr -52% y-y - Biosimilars revenue 2,809 Cr +3% y-y; EBITDA margin 22%, impacted by shipment timing; insulin capacity expanded - Generics revenue grew 10% y-y; EBITDA margin expanded over 700 bps y-y on better capacity and productivity - Services revenue down 9% y-y but up 13% q-q; margin improved 500 bps q-q on cost actions - Strong H2 FY27 expected with biosimilars launches, insulin capacity, generics profitability, and services recovery - Focus on margin improvement, free cash flow, debt reduction, and shareholder value creation